Keep strict vigil to prevent black marketing of COVID drug Remdesivir: Health Ministry to States

The Directorate General of Health Services under the Health Ministry has written to the Drug Controllers of the states to prevent sale of Remdesivir above MRP.

Published On 2020-07-09 07:22 GMT   |   Update On 2020-07-09 07:52 GMT

New Delhi: The Union Health Ministry has asked all the states to strengthen their vigil so that black marketing of Covid-19 drug Remdesivir is prevented.The Directorate General of Health Services under the Health Ministry has written to the Drug Controllers of the states to prevent sale of Remdesivir above MRP.The Central Drugs Standard Control Organisation has given approval for...

Login or Register to read the full article

New Delhi: The Union Health Ministry has asked all the states to strengthen their vigil so that black marketing of Covid-19 drug Remdesivir is prevented.

The Directorate General of Health Services under the Health Ministry has written to the Drug Controllers of the states to prevent sale of Remdesivir above MRP.

The Central Drugs Standard Control Organisation has given approval for the manufacturing and marketing of Remdesivir to Cipla, Hetro and Mylan.

The DGHS said that it has received a letter from LocalCircles routed through the Health Ministry, raising concerns over black marketing and overpricing of Remdesivir by certain unscrupulous persons.

"In view of the above, you are requested to instruct your enforcement officials to keep strict vigil on the matter to prevent black marketing and sale of Remdesivir injection above the MRP," the DGHS said in the letter to the states.

Read also: Cipla launches Cipremi at Rs 4,000 per vial


Tags:    
Article Source : IANS

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News